AI case study

SanofiDrug development and operations

Managers hedged budgets, leaving capital frozen. AI agents now reallocate funds in real time, freeing €1B for new discoveries.

Published|7 months ago

Key results

Capital Redeployed
~€1B
Out-of-Stock Reduction
80%
Asset Utilization
>10%

Result highlights

Unlock 3 result highlights

The story

Context

A global biopharmaceutical company faces massive R&D risks, where a single Phase III trial costs $500 million despite a 35% chance of failure.

Challenge

High attrition rates meant 90% of Phase I candidates failed, wasting years of development time. Additionally, defensive internal hedging during...

Solution
Unlock full story

Quotes

Unlock 7 more quotes

The company

Biopharmaceutical company specializing in immunology, vaccines, and rare diseases.

IndustryPharmaceuticals & Biotech
LocationParis, France
Employees50K-100K
Founded1973

The vendor

Provided agentic AI and LLM technology for Sanofi's end-to-end business transformation.

IndustrySoftware & Platforms
LocationSan Francisco, CA, USA
Employees1K-5K
Founded2015

The implementation partner

Formation Bio logo

Formation Bio

formation.bio
Role in this case study

Worked as an ecosystem partner to help Sanofi accelerate drug discovery and development via AI.

IndustryPharmaceuticals & Biotech
LocationNew York, NY, USA
Employees251-1K
Founded2013

Similar Case Studies

Related implementations across industries and use cases

56 AI case studies in Scientific Discovery

141 AI case studies in Pharmaceuticals & Biotech

33 AI case studies in Strategy